Bone marrow CD34+ cell count is predictive for adequate peripheral progenitor cell collection.
Several studies have investigated the influence of clinical and biological variables on mobilisation of peripheral blood progenitor cells (PBPCs). The aim of this study was to evaluate the role of steady-state bone marrow (BM) CD34+ cells as a predictive parameter of PBPC yield. We studied 90 patients with multiple myeloma (MM) (41 patients), non-Hodgkin's lymphoma (NHL) (25 patients) or acute myeloid leukaemia (AML) (24 patients), mobilised with chemotherapy and growth factor. The median time from first treatment to mobilisation was 5 months. Only one patient was previously exposed to alkylating agents. The median BM CD34+ count at mobilisation was 833 microl(-1) (range: 1.4-15.540) corresponding to 1.51% of mononuclear cells (range: 0.02-8.6). Sixty-six patients (73%) reached the optimal target of 4 x 10(6) kg(-1) CD34+ cells with 1 (18 patients), 2 (42 patients) or 3 leukaphereses (6 patients). Eleven patients (12%) mobilised less than 4 x 10(6) kg(-1) CD34+ cells and 13 (15%) failed mobilisation. Among the laboratory and clinical parameters evaluated at the time of mobilisation, only BM CD34+ count was a predictive factor for adequate collection (P = 0.04), particularly in MM patients (P = 0.003). In this setting, a BM concentration of CD34+ cells lower than 66 microL(-1) was associated with a higher probability of inadequate collection.
Corso
Alessandro
A
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Via Golgi 2, 27100 Pavia, Italy. a.corso@smatteo.pv.it
Varettoni
Marzia
M
Mangiacavalli
Silvia
S
Zappasodi
Patrizia
P
Klersy
Catherine
C
Rusconi
Chiara
C
Colucci
Emile
E
Lorenzi
Angela
A
Troletti
Daniela
D
Consensi
Erica
E
Lazzarino
Mario
M
D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis / Q000096:biosynthesis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000494:pharmacology; D001772:Blood Cell Count; D001854:Bone Marrow Cells / Q000166:cytology* / Q000187:drug effects / Q000502:physiology; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000494:pharmacology; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D011994:Recombinant Proteins
D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim